Loading...
WCLC congress 20202025-01-28T16:42:34+01:00

WCLC 2020 – virtual

Lecture Board: Maximilian Hochmair, MD; Luis M. Montuenga, PhD; Ross Soo, MB BS, PhD; Alexander Spira, MD, PhD
Medical Writer: Dr. Judith Moser

DOWNLOADS

All downloads from WCLC 2020

WCLC 2020 Cover

Full report (english)

WCLC Mandarin 2020

Full report (mandarin)

WCLC Japanese 2020

Full report (japanese)

EXPERT VIDEOS

All video interviews from virtual WCLC 2020

Alex Spira highlights the advantages, shortcomings and the future potential of antibody-drug conjugates, the balance between pro- and anti-inflammatory cytokines within the tumor microenvironment, and the preclinical evidence for targeting inflammatory cytokines in advanced or metastatic non-small cell lung cancer.

Luis M. Montuenga talks about factors that are impeding the implementation of low-dose computed tomography lung cancer screening at the global level and describes biomarkers/molecular technologies that are promising with respect to early detection of lung cancer. Moreover, he summarizes advantages and drawbacks of pan-cancer ctDNA analysis in liquid biopsy.

Ming Tsao relates to the innovations of the 5th edition of the WHO classification of lung tumors in terms of additional chapters, new tumor types and grading systems. Additionally, he discusses the use of organoids as potential platforms for drug testing and biomarker validation, as well as miRNAs for early lung cancer detection.

Sandip Patel discusses immunotherapy regimens for the treatment of patients with extended-stage SCLC, immune-related adverse events and how to identify, predict and prevent checkpoint-inhibitor induced pneumonitis. Additionally, he talks about post-pandemic cancer care delivery and what oncologists should keep in mind when using anti-PD-1 therapy.

Go to Top